Fidelity Advisor Biotechnology Fund Overview
Valuation check: FBTTX's ROE is 40.73%, above the sector sector average of 11.75%.
Get informed when a big investor buys or sells
+ Follow40.73%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for FBTTX is 40.73%. That is above the sector sector average of 11.75%. Investors often review this figure alongside Fidelity Advisor Biotechnology Fund's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, FBTTX currently prints 40.73% for ROE, while the sector average sits near 11.75%. That is roughly 246.5% above the sector mean. Large gaps often invite a closer look at Fidelity Advisor Biotechnology Fund's growth, margins, and balance sheet.
Return on Equity shows how effectively Fidelity Advisor Biotechnology Fund converts resources into returns. At 40.73%, FBTTX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting FBTTX's ROE (40.73%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
